48 Endocrine Care

Authors

A. Theil, C. Wilhelm, E. Guhr, J. Reinhardt, E. Bonifacio

Affiliation

DFG-Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany

Key words ▶ regulatory T cells ● ▶ regulatory T cell therapy ● ▶ diabetes mellitus type 1 ● ▶ autologous cord blood ●

Abstract

received 11.07.2014 accepted 22.09.2014 Bibliography DOI http://dx.doi.org/ 10.1055/s-0034-1394372 Published online: November 5, 2014 Horm Metab Res 2015; 47: 48–55 © Georg Thieme Verlag KG Stuttgart · New York ISSN 0018-5043 Correspondence Dr. A. Theil Preclinical Approaches to Stem Cell Therapy/Diabetes (Prof. Ezio Bonifacio) Technische Universität Dresden DFG-Center for Regenerative Therapies Dresden Cluster of Excellence Fetscherstrasse 105 01307 Dresden Germany Tel.:  + 49/351/458 82115 Fax:  + 49/351/458 82109 [email protected]



Cord blood has been used as a cell source for therapeutic purposes in children with type 1 diabetes and other disorders. Here, we explore the benefits of cord blood as an autologous source of T regulatory cells for immune cell therapy in patients. CD4 + CD25 +  T regulatory cells were isolated from cord blood and adult peripheral blood of healthy donors and compared during and after expansion in a 14-day protocol incorporating anti-CD3/anti-CD28 beads, and IL-2 with or without rapamycin. Cord blood T regulatory cells were largely naïve (89 ± 7 vs. 31 ± 10 % in young adults, p 

The relative merits of cord blood as a cell source for autologous T regulatory cell therapy in type 1 diabetes.

Cord blood has been used as a cell source for therapeutic purposes in children with type 1 diabetes and other disorders. Here, we explore the benefits...
813KB Sizes 0 Downloads 7 Views